FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897546422> ?p ?o ?g. }

• W2897546422 endingPage "S1009" @default.
• W2897546422 startingPage "S1009" @default.
• W2897546422 abstract "The authors evaluated the efficacy, patterns of failure, toxicity and cost of body gamma-ray stereotactic ablative radiotherapy (Body Gamma-ray SABR) for patients with medically inoperable, clinical stage I/II non-small cell lung cancer (NSCLC) with 8 years of follow-up. Clinical staging was performed according to the sixth edition of the American Joint Committee on Cancer TNM staging system. Eligible patients who had no previous treatments, with histologically confirmed NSCLC, determined as clinical stage I /II, underwent OUR-QGD type of the body gamma-ray SABR (70 grays in 10 fractions for gross target volume) at the Radiation Oncology Department, People's Liberation Army Airforce General Hospital, Beijing, China from January 2007 to July 2010. All patients were immobilized by vacuum bag, and then a slow CT scan was performed without any respiration gating. The total radiation dose of 50%, 60%, and 70% isodose line were prescribed in 50, 60, and 70 Grey (Gy) correspondingly, covering 100% of the planning target volume (PTV), 90% of the clinical target volume (CTV), and 80% of the gross target volume (GTV) in 10 fractions. The CT scan and/or positron emission tomography/computed tomography were every 3 months for the first 2 years, every 6 months for the next 3 years, and then annually thereafter to evaluate the efficacy of the treatment. The primary endpoint was overall survival. A total of 29 patients were eligible for analysis. The median age of the patients was 71 years (55-87), and the median follow-up was 8.1 years (6.8-10.3). The 1-year, 3-year, 5-year and 8-year overall survival rates were 93.1%, 72.1%, 59.4% and 44.8%, and the local, regional and distant disease recurrence were 10.3%, 13.8% and 13.8% at 5 years and 10.3%, 17.2% and 20.7% at 8 years. Two patients (6.9%) experienced grade 3 treatment-related adverse events. No patients developed grade 4 or 5 adverse events. The median cost of body gamma-ray SABR is 4838 dollars (4615-4923 dollars). With long-term follow-up, the results of the current study demonstrated outstanding local control and low toxicity after body gamma-ray SABR in patients with clinical stage I/II NSCLC. The dominant failure included regional and distant disease recurrence. And the body Gamma-ray SABR is pretty cost-effective." @default.
• W2897546422 created "2018-10-26" @default.
• W2897546422 creator A5005310392 @default.
• W2897546422 creator A5011868771 @default.
• W2897546422 creator A5015289492 @default.
• W2897546422 creator A5036485511 @default.
• W2897546422 creator A5041265150 @default.
• W2897546422 creator A5048720435 @default.
• W2897546422 creator A5070034379 @default.
• W2897546422 date "2018-10-01" @default.
• W2897546422 modified "2023-10-17" @default.
• W2897546422 title "P3.16-16 Long Term Outcomes of Body Gamma-Ray Stereotactic Ablative Radiotherapy for Patients with Stage I/II Non-Small Cell Lung Cancer" @default.
• W2897546422 doi "https://doi.org/10.1016/j.jtho.2018.08.1923" @default.
• W2897546422 hasPublicationYear "2018" @default.
• W2897546422 type Work @default.
• W2897546422 sameAs 2897546422 @default.
• W2897546422 citedByCount "0" @default.
• W2897546422 crossrefType "journal-article" @default.
• W2897546422 hasAuthorship W2897546422A5005310392 @default.
• W2897546422 hasAuthorship W2897546422A5011868771 @default.
• W2897546422 hasAuthorship W2897546422A5015289492 @default.
• W2897546422 hasAuthorship W2897546422A5036485511 @default.
• W2897546422 hasAuthorship W2897546422A5041265150 @default.
• W2897546422 hasAuthorship W2897546422A5048720435 @default.
• W2897546422 hasAuthorship W2897546422A5070034379 @default.
• W2897546422 hasBestOaLocation W28975464221 @default.
• W2897546422 hasConcept C106159729 @default.
• W2897546422 hasConcept C126322002 @default.
• W2897546422 hasConcept C126838900 @default.
• W2897546422 hasConcept C141071460 @default.
• W2897546422 hasConcept C146357865 @default.
• W2897546422 hasConcept C151730666 @default.
• W2897546422 hasConcept C162324750 @default.
• W2897546422 hasConcept C168563851 @default.
• W2897546422 hasConcept C187625094 @default.
• W2897546422 hasConcept C19617505 @default.
• W2897546422 hasConcept C203092338 @default.
• W2897546422 hasConcept C2776256026 @default.
• W2897546422 hasConcept C2780387249 @default.
• W2897546422 hasConcept C2989005 @default.
• W2897546422 hasConcept C509974204 @default.
• W2897546422 hasConcept C71924100 @default.
• W2897546422 hasConcept C85393063 @default.
• W2897546422 hasConcept C86803240 @default.
• W2897546422 hasConcept C91602232 @default.
• W2897546422 hasConceptScore W2897546422C106159729 @default.
• W2897546422 hasConceptScore W2897546422C126322002 @default.
• W2897546422 hasConceptScore W2897546422C126838900 @default.
• W2897546422 hasConceptScore W2897546422C141071460 @default.
• W2897546422 hasConceptScore W2897546422C146357865 @default.
• W2897546422 hasConceptScore W2897546422C151730666 @default.
• W2897546422 hasConceptScore W2897546422C162324750 @default.
• W2897546422 hasConceptScore W2897546422C168563851 @default.
• W2897546422 hasConceptScore W2897546422C187625094 @default.
• W2897546422 hasConceptScore W2897546422C19617505 @default.
• W2897546422 hasConceptScore W2897546422C203092338 @default.
• W2897546422 hasConceptScore W2897546422C2776256026 @default.
• W2897546422 hasConceptScore W2897546422C2780387249 @default.
• W2897546422 hasConceptScore W2897546422C2989005 @default.
• W2897546422 hasConceptScore W2897546422C509974204 @default.
• W2897546422 hasConceptScore W2897546422C71924100 @default.
• W2897546422 hasConceptScore W2897546422C85393063 @default.
• W2897546422 hasConceptScore W2897546422C86803240 @default.
• W2897546422 hasConceptScore W2897546422C91602232 @default.
• W2897546422 hasIssue "10" @default.
• W2897546422 hasLocation W28975464221 @default.
• W2897546422 hasOpenAccess W2897546422 @default.
• W2897546422 hasPrimaryLocation W28975464221 @default.
• W2897546422 hasRelatedWork W1941481372 @default.
• W2897546422 hasRelatedWork W2040306711 @default.
• W2897546422 hasRelatedWork W2051068854 @default.
• W2897546422 hasRelatedWork W2582454241 @default.
• W2897546422 hasRelatedWork W2801975490 @default.
• W2897546422 hasRelatedWork W2939422089 @default.
• W2897546422 hasRelatedWork W3029134866 @default.
• W2897546422 hasRelatedWork W4310082075 @default.
• W2897546422 hasRelatedWork W793192164 @default.
• W2897546422 hasRelatedWork W2777338963 @default.
• W2897546422 hasVolume "13" @default.
• W2897546422 isParatext "false" @default.
• W2897546422 isRetracted "false" @default.
• W2897546422 magId "2897546422" @default.
• W2897546422 workType "article" @default.